Fortrea Holdings (FTRE)

Overall impact
B (75)

Commentary

Fortrea Holdings is a strong overall performer. With a 'B' rating of 74.6 for overall impact (88th percentile compared to all companies), Fortrea Holdings ranks 158th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 154 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 424 others. On top material causes for Fortrea Holdings's industry (Pharmaceuticals & Biotech), Fortrea Holdings performs well in Reduced Green House Gas Emissions (86.8 score), Racial Justice and Civil Rights (87.4), Access to Affordable Healthcare (96.0) and 4 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (34.0 score) and Sustainable Use of Water (21.9).
Impact
Cause FTRE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2022
Employees
14,000
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nc, United States
Share classes
FTRE
Description
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Material causes
Ethos considers the following causes material for Fortrea Holdings, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.